Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
(Updates share movement, adds details and analyst comment in bullets 5 and 6) Oct 13 (Reuters) — BioNTech said on Tuesday its experimental mRNA cancer immunotherapy failed to meet the first main goal of a mid-to-late-stage trial in patients with head and neck cancer. US-listed shares of the drug developer were down nea
BioNTech said its experimental mRNA cancer immunotherapy failed to meet the first main goal of a mid-to-late-stage trial in patients with head and neck cancer. Its US-listed shares were down nearly 3% in early trading.
BioNTech said its experimental mRNA cancer immunotherapy failed to meet the first main goal of a mid-to-late-stage trial in patients with head and neck cancer. Its U.S.-listed shares were down nearly 6% in premarket trading.